← Back to Search

Other

PRO1160 for Advanced Cancer

Phase 1 & 2

Recruiting

Research Sponsored by ProfoundBio US Co.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status 0 or 1

Pathologically confirmed metastatic or unresectable solid malignancy including Renal Cell carcinoma, Nasopharyngeal carcinoma or Stage III or IV Non Hodgkin Lymphoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through end of treatment, up to approximately 1 year

Awards & highlights

Study Summary

This trial will evaluate the safety and effectiveness of a drug, PRO1160, for treating solid tumors and cancers that have spread through the body or cannot be removed with surgery.

Who is the study for?

This trial is for adults with advanced cancers like kidney cancer, nasopharyngeal cancer, or stage III/IV non-Hodgkin's lymphoma that have worsened after treatment. Participants must be able to provide a tumor sample and should not have had certain other cancers in the last 3 years or been treated with anti-CD70 therapy.Check my eligibility

What is being tested?

PRO1160 is being tested on participants with solid tumors or liquid cancers that are metastatic or unresectable. The study has two parts: Part A determines the best dose and schedule of PRO1160; Part B assesses its safety and effectiveness at the determined dose against specific types of cancer.See study design

What are the potential side effects?

While detailed side effects are not listed, as this is an early-phase trial for PRO1160, potential side effects typically include reactions at the infusion site, fatigue, nausea, changes in blood counts leading to increased infection risk or bleeding tendencies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am fully active or can carry out light work.

Select...

My cancer is advanced and cannot be surgically removed.

Select...

My condition worsened or didn't improve after treatment known to help.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through end of treatment, up to approximately 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through end of treatment, up to approximately 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through end of treatment, up to approximately 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting toxicity

Incidence of Treatment-Emergent Adverse Events

Secondary outcome measures

Disease Control Rate

Duration of objective response

Objective Response Rate

+2 more

Other outcome measures

Immunogenic potential of PRO1160

Trial Design

1Treatment groups

Experimental Treatment

Group I: PRO1160Experimental Treatment1 Intervention

PRO1160 monotherapy in escalating doses in Part A and at the recommended phase 2 dose in Part B

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

ProfoundBio US Co.Lead Sponsor

2 Previous Clinical Trials

348 Total Patients Enrolled

Media Library

PRO1160 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05721222 — Phase 1 & 2

Non-Hodgkin's Lymphoma Research Study Groups: PRO1160

Non-Hodgkin's Lymphoma Clinical Trial 2023: PRO1160 Highlights & Side Effects. Trial Name: NCT05721222 — Phase 1 & 2

PRO1160 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05721222 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many healthcare facilities are currently conducting this research trial?

"This research is five sites, including the Providence Cancer Institute in Portland, Sarah Canon Research Institute in Nashville and The University of Texas-MD Anderson Cncer Center in Houston. Additionally, two additional centres are providing this study."

Answered by AI

Is there currently a call for participants in this research study?

"Presently, clinicaltrials.gov states that recruitment for this medical trial has been suspended; it was initially posted on March 1st 2023 and last updated in January of the following year. Although no longer enrolling patients, 4296 other studies are actively searching for participants."

Answered by AI

What objectives is this clinical experiment striving to fulfill?

"The primary end point of this clinical trial, to be evaluated over the course of one year, is dose-limiting toxicity. Secondary objectives include disease control rate based on RECIST v1.1 (RCC and NPC) and Lugano Classification 2014 (NHL), duration of objective response measured from initial documentation to tumor progression or death, as well as progression-free survival calculated between start date and first recorded disease development or mortality."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)

2023. "PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05721222.

All > Nasopharyngeal Carcinoma